Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 2, 2011, Pages 253-263

  Daly, Ann K ^a   Ballestri, Stefano ^b   Carulli, Lucia ^b   Loria, Paola ^b   Day, Christopher P ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

gene; genome wide association study; NAFLD; oxidative stress; PNPLA3; polymorphism

Indexed keywords

PREGNANE X RECEPTOR;

ADIPOQ GENE; APOC3 GENE; ATGR1 GENE; CD14 GENE; COL13A1 GENE; DISEASE SEVERITY; ENDOPLASMIC RETICULUM STRESS; ENPP1 GENE; ETHNICITY; FDFT1 GENE; GCLC GENE; GENE; GENE CLUSTER; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HFE GENE; HOMOZYGOSITY; HUMAN; IL 6 GENE; INSULIN RESISTANCE; IRS1 GENE; KLF6 GENE; LIPID METABOLISM; LIPOTOXICITY; MOLECULAR DYNAMICS; MTP GENE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; PEMT GENE; PNPLA3 GENE; PREDICTION; PROTEIN SYNTHESIS; PXR GENE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOD2 GENE; TNF ALPHA GENE; UGT1A1 GENE;

ANIMALS; CYTOKINES; DISEASE PROGRESSION; FATTY LIVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INFLAMMATION MEDIATORS; LIPASE; LIPID METABOLISM; LIVER CIRRHOSIS; MALE; MEMBRANE PROTEINS; MICE; OXIDATIVE STRESS; POLYMORPHISM, GENETIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 79954507610     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.11.18     Document Type: Review

References (82)

1. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37(5), 1202-1219 (2003). (Pubitemid 36538699)
2. De Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J. Hepatol. 48 (Suppl. 1), S104-S112 (2008).
3. Day CP. From fat to infammation. Gastroenterology 130(1), 207-210 (2006).
4. Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin. Liver Dis. 27(1), 44-54 (2007).
5. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12(5), 1106-1110 (1990).
6. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fbrosis in the severely obese. Gastroenterology 121(1), 91-100 (2001). (Pubitemid 32591518)
7. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology 40(1), 46-54 (2004). (Pubitemid 38868922)
8. Tilg H, Moschen AR. Evolution of infammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52(5), 1836-1846 (2010).
9. Alkhouri N, Dixon LJ, Feldstein AE. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev. Gastroenterol. Hepatol. 3(4), 445-451 (2009).
10. Mari M, Caballero F, Colell A et al. Mitochondrial free cholesterol loading sensitizes to TNF-and Fas-mediated steatohepatitis. Cell Metab. 4(3), 185-198 (2006). (Pubitemid 44307975)
11. Schwimmer JB, Celedon MA, Lavine JE et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 136(5), 1585-1592 (2009).
12. Makkonen J, Pietilainen KH, Rissanen A, Kaprio J, Yki-Jarvinen H. Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. J. Hepatol. 50(5), 1035-1042 (2009).
13. Loomba R, Hwang SJ, O'Donnell CJ et al. Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham heart study Gastroenterology 134(4), 953-959 (2008).
14. Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am. J. Med. 108(1), 9-13 (2000). (Pubitemid 30058272)
15. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am. J. Gastroenterol. 96(10), 2957-2961 (2001). (Pubitemid 32959539)
16. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (6), 1387-1395 (2004). (Pubitemid 39657013)
17. Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am. J. Gastroenterol. 99(2), 292-298 (2004). (Pubitemid 38279872)
18. Guerrero R, Vega GL, Grundy SM, Browning JD. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology 49(3), 791-801 (2009).
19. Williams CH, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study Gastroenterology 140(1), 124-131 (2010).
20. Hirschhorn JN. Genomewide association studies-illuminating biologic pathways. N Engl. J. Med. 360(17), 1699-1701 (2009).
21. International HapMap Consortium. A haplotype map of the human genome. Nature 437(7063), 1299-1320 (2005).
22. Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease. J. Clin. Invest. 118(5), 1590-1605 (2008). (Pubitemid 351632361)
23. Hardy J, Singleton A. Genomewide association studies and human disease. N Engl. J. Med. 360(17), 1759-1768 (2009).
24. Wellcome Trust Case Control Consortium.Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447(7145), 661-678 (2007).
25. Hirschfeld GM, Liu X, Xu C et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl. J. Med. 360, 2544-2555 (2009).
26. Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 40(12), 1461-1465 (2008).
27. Chalasani N, Guo X, Loomba R et al. Genome-wide association study identifes variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 139(5), 1567-1576 (2010).
28. Lonardo A, Caldwell SH, Loria P. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. Expert Rev. Endocrinol. Metab. 5(3), 403-423 (2010).
29. Weyrich P, Stefan N, Haring HU, Laakso M, Fritsche A. Effect of genotype on success of lifestyle intervention in subjects at risk for Type 2 diabetes. J. Mol. Med. 85(2), 107-117 (2007). (Pubitemid 46183610)
30. He S, McPhaul C, Li JZ et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J. Biol. Chem. 285(9), 6706-6715 (2010).
31. Yuan X, Waterworth D, Perry JR et al. Population-based genome-wide association studies reveal six loci infuencing plasma levels of liver enzymes. Am. J. Hum. Genet 83(4), 520-528 (2008).
32. Kotronen A, Peltonen M, Hakkarainen A et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 137(3), 865-872 (2009).
33. Sookoian S, Castano GO, Burgueno AL, Gianotti TF, Rosselli MS, Pirola CJ. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity J. Lipid Res. 50(10), 2111-2116 (2009).
34. Valenti L, Al-Serri A, Daly AK et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I 148M polymorphism infuences liver fbrosis in patients with nonalcoholic fatty liver disease. Hepatology 51(4), 1209-1217 (2010).
35. Romeo S, Sentinelli F, Cambuli VM et al. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J. Hepatol. 53(2), 335-338 (2010).
36. Speliotes EK, Butler JL, Palmer CD, Voight BF, Hirschhorn JN. PNPLA3 variants specifcally confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 52(3), 904-912 (2010).
37. Valenti L, Alisi A, Galmozzi E et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 52(4), 1274-1280 (2010).
38. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 52(3), 894-903 (2010).
39. Santoro N, Kursawe R, DAdamo E et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 52(4), 1281-1290 (2010).
40. Kantartzis K, Peter A, Machicao F et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 58(11), 2616-2623 (2009).
41. Namikawa C, Shu-Ping Z, Vyselaar JR et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J. Hepatol. 40(5), 781-786 (2004). (Pubitemid 38507358)
42. Bernard S, Touzet S, Personne I et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with Type II diabetes. Diabetologia 43(8), 995-999 (2000). (Pubitemid 30655718)
43. Gambino R, Cassader M, Pagano G, Durazzo M, Musso G. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profle in NASH? Hepatology 45(5), 1097-1107 (2007). (Pubitemid 46775771)
44. Oliveira CP, Stefano JT, Cavaleiro AM et al. Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 25(2), 357-361 (2010).
45. Dong H, Wang J, Li C et al. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J. Hepatol. 46(5), 915-920 (2007). (Pubitemid 46529040)
46. Song J, da Costa KA, Fischer LM et al. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J. 19(10), 1266-1271 (2005). (Pubitemid 41113723)
47. Zhang B, Xie W, Krasowski MD. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 9(11), 1695-1709 (2008).
48. Zhou J, Zhai Y, Mu Y et al. A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway J. Biol. Chem. 281 (21), 15013-15020 (2006). (Pubitemid 43855205)
49. Sookoian S, Castano GO, Burgueno AL, Gianotti TF, Rosselli MS, Pirola CJ. The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmacogenet. Genomics 20(1), 1-8 (2010).
50. Petersen KF, Dufour S, Hariri A et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N. Engl. J. Med. 362(12), 1082-1089 (2010).
51. Kozlitina J, Boerwinkle E, Cohen JC, Hobbs HH. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 53(2), 467-474 (2011).
52. Tarugi P, Lonardo A, Gabelli C et al. Phenotypic expression of familial hypobet alipoproteinemia in three kindreds with mutations of apolipoprotein B gene. J. Lipid Res. 42(10), 1552-1561 (2001). (Pubitemid 33020087)
53. Tarugi P, Lonardo A, Ballarini G et al. A study of fatty liver disease and plasma lipoproteins in a kindred with familial hypobet alipoproteinemia due to a novel truncated form of apolipoprotein B (APO B-54.5). J. Hepatol. 33(3), 361-370 (2000). (Pubitemid 30663372)
54. Amaro A, Fabbrini E, Kars M et al. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobet alipoproteinemia. Gastroenterology 139(1), 149-153 (2010).
55. Dongiovanni P, Valenti L, Rametta R et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 59(2), 267-273 (2010).
56. Carulli L, Canedi I, Rondinella S et al. Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. Dig. Liver Dis. 41(11), 823-828 (2009).
57. Musso G, Gambino R, De Michieli F, Durazzo M, Pagano G, Cassader M. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH. Hepatology 47(4), 1167-1177 (2008). (Pubitemid 351547903)
58. Nobili V, Daly AK, Al-Serri A, Leathart JB, Day CP. The mitochondrial superoxide dismutase 2 (SOD2) targeting sequence polymorphism is associated with fbrotic NAFLD: consistent evidence from case-control and intra-familial allelic association studies. Hepatology 46, 760A (2007).
59. Chen Y, Yang Y, Miller ML et al. Hepatocyte-specifc GCLC deletion leads to rapid onset of steatosis with mitochondrial injury and liver failure. Hepatology 45(5), 1118-1128 (2007). (Pubitemid 46775773)
60. Lin YC, Chang PF, Hu FC, Chang MH, Ni YH. Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease. Pediatrics 124(6), e1221-e1227 (2009).
61. George DK, Goldwurm S, MacDonald GA et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fbrosis. Gastroenterology 114(2), 311-318 (1998). (Pubitemid 28093538)
62. Kowdley KV. The role of iron in nonalcoholic fatty liver disease: the story continues. Gastroenterology 138(3), 817-819 (2010).
63. Nelson JE, Bhattacharya R, Lindor KD et al. HFE C282Y mutations are associated with advanced hepatic fbrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology 46(3), 723-729 (2007). (Pubitemid 47436118)
64. Valenti L, Fracanzani AL, Bugianesi E et al. HFE genotype, parenchymal iron accumulation, and liver fbrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 138(3), 905-912 (2010).
65. Nelson JE, Wilson L, Brunt EM et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology (2010).
66. Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FD. A polymorphism in the 5́ fanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am. J. Respir. Cell Mol. Biol. 20(5), 976-983 (1999). (Pubitemid 129540855)
67. Day CP, Leathart J, McTernan P, Mathew C, Daly A. Genetic evidence for a role of gut fora in the pathogenesis of NASH in humans. Hepatology 44(Suppl. 1), 261A (2006).
68. Valenti L, Fracanzani AL, Dongiovanni P et al. Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 122(2), 274-280 (2002). (Pubitemid 34116980)
69. Tokushige K, Takakura M, Tsuchiya-Matsushita N, Taniai M, Hashimoto E, Shiratori K. Infuence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J. Hepatol. 46(6), 1104-1110 (2007). (Pubitemid 46669735)
70. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fbrosis: a critical appraisal. Hepatology 37(3), 493-503 (2003). (Pubitemid 36258768)
71. Dixon JB, Bhathal PS, Jonsson JR, Dixon AF, Powell EE, O'Brien PE. Pro-fbrotic polymorphisms predictive of advanced liver fbrosis in the severely obese. J. Hepatol. 39(6), 967-971 (2003). (Pubitemid 37523767)
72. Yoneda M, Hotta K, Nozaki Y et al. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int. 29(7), 1078-1085 (2009).
73. Georgescu EF. Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a frst-class option? Adv. Ther. 25, 1141-1174 (2008).
74. Ratziu V, Lalazar A, Wong L et al. Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fbrosis. Proc. Natl Acad. Sci. USA 95(16), 9500-9505 (1998). (Pubitemid 28506260)
75. Starkel P, Sempoux C, Leclercq I et al. Oxidative stress, KLF6 and transforming growth factor-ß up-regulation differentiate non-alcoholic steatohepatitis progressing to fbrosis from uncomplicated steatosis in rats. J. Hepatol. 39(4), 538-546 (2003). (Pubitemid 37204653)
76. Narla G, Difeo A, Reeves HL et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res. 65(4), 1213-1222 (2005). (Pubitemid 40270146)
77. Miele L, Beale G, Patman G et al. The Kruppel-like factor 6 genotype is associated with fbrosis in nonalcoholic fatty liver disease. Gastroenterology 135(1), 282-291 e281 (2008).
78. Goldstein DB. Common genetic variation and human traits. N. Engl. J. Med. 360(17), 1696-1698 (2009).
79. Musunuru K, Pirruccello JP, Do R et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N. Engl. J. Med. 363(23), 2220-2227 (2010).
80. Sookoian S, Rosselli MS, Gemma C et al. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor g coactivator 1a promoter. Hepatology 52(6), 1992-2000 (2010).
81. Billings LK, Florez JC. The genetics of Type 2 diabetes: what have we learned from GWAS? Ann. NY Acad. Sci. 1212, 59-77 (2010).
82. Bugianesi E, Manzini P, D'Antico S et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fbrosis in nonalcoholic fatty liver. Hepatology 39(1), 179-187 (2004). (Pubitemid 38461480)